We are analyzing https://link.springer.com/article/10.1007/s10549-021-06128-4.

Title:
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients | Breast Cancer Research and Treatment
Description:
Purpose We recently reported results of a phase II trial that camrelizumab plus apatinib induced an objective response rate (ORR) at 43.3% in advanced triple-negative breast cancer (TNBC). This study presents analysis of potential biomarkers. Methods TILs, CD8+ T cells and PD-1/PD-L1 expression were evaluated in tumor samples by immunohistochemistry. 59 Cytokines/chemokines, growth factors, or checkpoint-related proteins, blood immune cell subpopulations were analyzed in blood samples by multiplexed bead immunoassays or flow cytometry. Correlation between biomarkers and clinical outcomes including ORR, progression-free survival (PFS), and overall survival (OS) was analyzed. Results 28 Patients had biopsies and blood collected. Baseline TILs were significantly associated with longer PFS (P = 0.035). An increase of tumor-infiltrating CD8+ T cells > 15% during therapy was associated with higher ORR (P = 0.040). Patients with lower baseline plasma levels of HGF or IL-8 were more likely to respond to treatment (P = 0.005 or 0.001, respectively), and showed a longer PFS and OS. Patients with a decrease of IL-8, or an increase of TIM-3 or CD152 during treatment responded more to treatment (P = 0.008, 0.040, or 0.014, respectively). Responders had a higher baseline CD4+ T cells and B cell proportions in blood than non-responders (P = 0.002 and 0.030, respectively). Conclusion Higher baseline TILs or a greater increase of tumor-infiltrating CD8+ T cells during therapy, lower baseline plasma HGF/IL-8, a decrease of plasma IL-8, an increase of plasma TIM-3/CD152 during therapy, higher baseline CD4+ T cells or B cells proportion in blood are potential biomarkers for combinational anti-angiogenesis and immunotherapy in advanced TNBC patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cancer, article, pubmed, breast, google, scholar, cas, patients, cells, triplenegative, liu, wang, httpsdoiorgs, central, treatment, research, advanced, survival, res, response, phase, baseline, immunotherapy, zhang, trial, study, blood, analysis, biomarkers, access, treat, oncol, content, tils, immune, clinical, sun, metastatic, nature, privacy, cookies, information, results, tumor, cell, tumorinfiltrating, therapy, open, author, zhou,

Topics {✒️}

month download article/chapter triple-negative breast cancer triple-negative breast cancer triple-negative breast cancers combinational anti-angiogenesis anti-pd-l1 antibody pd-1/pd-l1 expression lymph node-negative disease van den boorn-konijnenberg her2-positive breast cancer immune checkpoint blockade increased pd-l1 expression sun yat-sen university real-life esme cohort breast cancer access anti-pd-1 immunotherapy qiang liu metastatic breast cancer full article pdf long-term clinical outcomes van den eynden anti-pd-1 treatment metaplastic breast cancer study presents analysis reis-filho js article liu privacy choices/manage cookies population-based analysis triple-negative breast tumor center breast cancer subtypes cancer immunotherapy landscape fundamental research funds phase 1b–2 trial international ethical guidelines central universities code availability biomarker analyses related subjects bmc cancer 19 phase ii trial immune-checkpoint inhibitors checkpoint-related proteins long-term follow prognostic characteristics ethics declarations conflict predictive markers tumor-infiltrating lymphocytes breast cancer article log

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients
         description:We recently reported results of a phase II trial that camrelizumab plus apatinib induced an objective response rate (ORR) at 43.3% in advanced triple-negative breast cancer (TNBC). This study presents analysis of potential biomarkers. TILs, CD8+ T cells and PD-1/PD-L1 expression were evaluated in tumor samples by immunohistochemistry. 59 Cytokines/chemokines, growth factors, or checkpoint-related proteins, blood immune cell subpopulations were analyzed in blood samples by multiplexed bead immunoassays or flow cytometry. Correlation between biomarkers and clinical outcomes including ORR, progression-free survival (PFS), and overall survival (OS) was analyzed. 28 Patients had biopsies and blood collected. Baseline TILs were significantly associated with longer PFS (P = 0.035). An increase of tumor-infiltrating CD8+ T cells > 15% during therapy was associated with higher ORR (P = 0.040). Patients with lower baseline plasma levels of HGF or IL-8 were more likely to respond to treatment (P = 0.005 or 0.001, respectively), and showed a longer PFS and OS. Patients with a decrease of IL-8, or an increase of TIM-3 or CD152 during treatment responded more to treatment (P = 0.008, 0.040, or 0.014, respectively). Responders had a higher baseline CD4+ T cells and B cell proportions in blood than non-responders (P = 0.002 and 0.030, respectively). Higher baseline TILs or a greater increase of tumor-infiltrating CD8+ T cells during therapy, lower baseline plasma HGF/IL-8, a decrease of plasma IL-8, an increase of plasma TIM-3/CD152 during therapy, higher baseline CD4+ T cells or B cells proportion in blood are potential biomarkers for combinational anti-angiogenesis and immunotherapy in advanced TNBC patients.
         datePublished:2021-02-25T00:00:00Z
         dateModified:2021-02-25T00:00:00Z
         pageStart:687
         pageEnd:697
         sameAs:https://doi.org/10.1007/s10549-021-06128-4
         keywords:
            Biomarker analysis
            PD-1 blockade
            Anti-angiogenesis
            Triple-negative breast cancer
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig6_HTML.png
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:186
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jieqiong Liu
               affiliation:
                     name:Sun Yat-sen University
                     address:
                        name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Ying Li
               affiliation:
                     name:Sun Yat-sen University
                     address:
                        name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Qian Li
               affiliation:
                     name:Sun Yat-sen University
                     address:
                        name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dandan Liang
               affiliation:
                     name:Genecast Precision Medicine Technology Institute
                     address:
                        name:Genecast Precision Medicine Technology Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Quanren Wang
               affiliation:
                     name:Jiangsu Hengrui Medicine Co., Ltd.
                     address:
                        name:Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Qiang Liu
               url:http://orcid.org/0000-0002-5451-4862
               affiliation:
                     name:Sun Yat-sen University
                     address:
                        name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients
      description:We recently reported results of a phase II trial that camrelizumab plus apatinib induced an objective response rate (ORR) at 43.3% in advanced triple-negative breast cancer (TNBC). This study presents analysis of potential biomarkers. TILs, CD8+ T cells and PD-1/PD-L1 expression were evaluated in tumor samples by immunohistochemistry. 59 Cytokines/chemokines, growth factors, or checkpoint-related proteins, blood immune cell subpopulations were analyzed in blood samples by multiplexed bead immunoassays or flow cytometry. Correlation between biomarkers and clinical outcomes including ORR, progression-free survival (PFS), and overall survival (OS) was analyzed. 28 Patients had biopsies and blood collected. Baseline TILs were significantly associated with longer PFS (P = 0.035). An increase of tumor-infiltrating CD8+ T cells > 15% during therapy was associated with higher ORR (P = 0.040). Patients with lower baseline plasma levels of HGF or IL-8 were more likely to respond to treatment (P = 0.005 or 0.001, respectively), and showed a longer PFS and OS. Patients with a decrease of IL-8, or an increase of TIM-3 or CD152 during treatment responded more to treatment (P = 0.008, 0.040, or 0.014, respectively). Responders had a higher baseline CD4+ T cells and B cell proportions in blood than non-responders (P = 0.002 and 0.030, respectively). Higher baseline TILs or a greater increase of tumor-infiltrating CD8+ T cells during therapy, lower baseline plasma HGF/IL-8, a decrease of plasma IL-8, an increase of plasma TIM-3/CD152 during therapy, higher baseline CD4+ T cells or B cells proportion in blood are potential biomarkers for combinational anti-angiogenesis and immunotherapy in advanced TNBC patients.
      datePublished:2021-02-25T00:00:00Z
      dateModified:2021-02-25T00:00:00Z
      pageStart:687
      pageEnd:697
      sameAs:https://doi.org/10.1007/s10549-021-06128-4
      keywords:
         Biomarker analysis
         PD-1 blockade
         Anti-angiogenesis
         Triple-negative breast cancer
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-021-06128-4/MediaObjects/10549_2021_6128_Fig6_HTML.png
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:186
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jieqiong Liu
            affiliation:
                  name:Sun Yat-sen University
                  address:
                     name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Ying Li
            affiliation:
                  name:Sun Yat-sen University
                  address:
                     name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Qian Li
            affiliation:
                  name:Sun Yat-sen University
                  address:
                     name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dandan Liang
            affiliation:
                  name:Genecast Precision Medicine Technology Institute
                  address:
                     name:Genecast Precision Medicine Technology Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Quanren Wang
            affiliation:
                  name:Jiangsu Hengrui Medicine Co., Ltd.
                  address:
                     name:Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Qiang Liu
            url:http://orcid.org/0000-0002-5451-4862
            affiliation:
                  name:Sun Yat-sen University
                  address:
                     name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:186
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Sun Yat-sen University
      address:
         name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
         type:PostalAddress
      name:Sun Yat-sen University
      address:
         name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
         type:PostalAddress
      name:Sun Yat-sen University
      address:
         name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
         type:PostalAddress
      name:Genecast Precision Medicine Technology Institute
      address:
         name:Genecast Precision Medicine Technology Institute, Beijing, China
         type:PostalAddress
      name:Jiangsu Hengrui Medicine Co., Ltd.
      address:
         name:Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China
         type:PostalAddress
      name:Sun Yat-sen University
      address:
         name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jieqiong Liu
      affiliation:
            name:Sun Yat-sen University
            address:
               name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Ying Li
      affiliation:
            name:Sun Yat-sen University
            address:
               name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
               type:PostalAddress
            type:Organization
      name:Qian Li
      affiliation:
            name:Sun Yat-sen University
            address:
               name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
               type:PostalAddress
            type:Organization
      name:Dandan Liang
      affiliation:
            name:Genecast Precision Medicine Technology Institute
            address:
               name:Genecast Precision Medicine Technology Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Quanren Wang
      affiliation:
            name:Jiangsu Hengrui Medicine Co., Ltd.
            address:
               name:Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China
               type:PostalAddress
            type:Organization
      name:Qiang Liu
      url:http://orcid.org/0000-0002-5451-4862
      affiliation:
            name:Sun Yat-sen University
            address:
               name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
      name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
      name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
      name:Genecast Precision Medicine Technology Institute, Beijing, China
      name:Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China
      name:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(180)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.56s.

LINK . SPRINGER . COM {}